Evidence for Complement-mediated Bone Marrow Necrosis in a Young Adult with Sickle Cell Disease
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Inflammatory pathways and anti-inflammatory therapies in sickle cell disease.
Tozatto-Maio K, Ros F, Weinlich R, Rocha V Hemasphere. 2024; 8(12):e70032.
PMID: 39698332 PMC: 11655128. DOI: 10.1002/hem3.70032.
Complement in Sickle Cell Disease: Are We Ready for Prime Time?.
Varelas C, Tampaki A, Sakellari I, Anagnostopoulos A, Gavriilaki E, Vlachaki E J Blood Med. 2021; 12:177-187.
PMID: 33790681 PMC: 8001680. DOI: 10.2147/JBM.S287301.
References
1.
Park S, Matte A, Jung Y, Ryu J, Anand W, Han E
. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion. Blood. 2020; 135(23):2071-2084.
PMC: 7273832.
DOI: 10.1182/blood.2019002227.
View
2.
Janssens A, Offner F, Van Hove W
. Bone marrow necrosis. Cancer. 2000; 88(8):1769-80.
View
3.
CHARACHE S, Page D
. Infarction of bone marrow in the sickle cell disorders. Ann Intern Med. 1967; 67(6):1195-200.
DOI: 10.7326/0003-4819-67-6-1195.
View
4.
Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E
. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Hemoglobin. 2019; 42(5-6):339-341.
DOI: 10.1080/03630269.2018.1540353.
View
5.
Merle N, Boudhabhay I, Leon J, Fremeaux-Bacchi V, Roumenina L
. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Transfus Clin Biol. 2019; 26(2):116-124.
DOI: 10.1016/j.tracli.2019.02.008.
View